Impact of GLP-1 Agonists in Patients With Atrial Fibrillation Ablation
Document Type
Conference Proceeding
Publication Date
5-2024
Publication Title
Heart Rhythm
Abstract
Background: Cardiovascular benefits of Glucagon-like Peptide1 Receptor (GLP-1) agonists in patients with type 2 diabetes mellitus (DM) are increasingly being recognized. However, its impact in patients with DM undergoing catheter ablation is not well described. Objective: To evaluate the impact of GLP-1 agonist therapy in patients with DM who underwent AF ablation. Methods: Utilizing the TriNetX research network, we identified, by means of Current Procedural Terminology (CPT) codes, patients with ≥18 years of age with DM who underwent AF ablation from January 1, 2015 to December 1, 2022. Patients with DM were stratified based on their baseline GLP-1 agonist use to create two cohorts. After propensity-score matching, there were 2,894 patients in each cohort. The primary outcome was a composite of cardioversion, initiation of new antiarrhythmic drug therapy (AAD), or re-do AF ablation. Secondary outcomes included AF readmissions, heart failure readmissions, readmissions due to ischemic stroke and mortality. Follow-up period was 12 months. Results: GLP-1 agonist use in patients with DM undergoing AF ablation was associated with significantly reduced composite risk of post-procedure cardioversion, new antiarrhythmic drug therapy and re-do AF ablation [adjusted OR: 0.75 (95% CI: 0.70 - 0.80); p , 0.0001)] (Table 1; Figure 1). At 12 months, patients on GLP-1 agonists had an overall lower mortality [adjusted OR: 0.63 (95% CI: 0.47 - 0.84); p 5 0.001)], AF readmission [adjusted OR: 0.87 (95% CI: 0.78 - 0.97); p , 0.0001)], HF readmissions [adjusted OR: 0.73 (95% CI: 0.62 - 0.86); p , 0.004)]. However, no difference was noted in ischemic stroke between the two groups [adjusted OR: 0.85 (95% CI: 0.45 - 1.58); p 5 0.924)]. Conclusion: The use of GLP-1 agonist in patients with type 2 DM is associated with a lower risk of AF recurrence after ablation and therefore, a reduced need for cardioversion, new antiarrhythmic drug therapy and overall reduced mortality
Volume
21
Issue
5S
First Page
S41
Last Page
S42
Recommended Citation
Sheth A, Patel H, Kowlgi GN, Mehta N, Del Carpio Munoz F, DeSimone CV, et al. Impact of GLP-1 agonists in patients with atrial fibrillation ablation. Heart Rhythm. 2024 May;21(5S):S41-S42. doi:10.1016/j.hrthm.2024.03.334
DOI
10.1016/j.hrthm.2024.03.334
Comments
Heart Rhythm Society Annual Meeting, May 16-19, 2024, Boston, MA